Abstract
Introduction: With the advent of topical timolol, there has been a tremendous change in the management of infantile hemangiomas. Aims: The aim of the study was to evaluate the treatment response with topical 0.5% timolol drops in 20 children of infantile hemangiomas. Methods: The response to treatment was seen as regression of growth or flattening of lesion or lightening of the surface. Timolol drops 0.5% were applied over the hemangiomas and three drops were applied twice daily. Results: Head-and-neck involvement was seen in 40% of the infants, the trunk was involved in 30% of the infants, the limbs were involved in 25% of the infants, and the genitalia were involved in 5% of the infants. Response to treatment with timolol was excellent in 60% of the infants, very good in 20% of the infants, good in 15% of the infants, average in 5% of the infants, and none of the infants showed poor response. Regarding the side effects of topical timolol, sleep disturbances and poor feeding were seen in 5% of the infants. Discussion: Timolol is used for hemangiomas that do not involute spontaneously or for infected or ulcerated hemangiomas or those hemangiomas in which there is a risk of scarring, disfigurement, or impairment of vital structures.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call